While the results are not necessarily generalizable to resource-limited settings, the finding is consistent with other studies demonstrating better clinical outcomes and reduced mortality when ART is initiated for everyone with less than 350 CD4+ cells/mm3, including the landmark Comprehensive International Program of Research on AIDS (CIPRA) HT001 study conducted in Haiti. The gene discussed is CD4; the disease is AIDS.